Related Videos
Video
ASCO26: Sara Tolaney, MD, MPH, ASCENT-03
Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.
Video
ASCO26: Sara Tolaney, MD, MPH, ASCENT-04
Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free ...
Video
ESMO Breast Cancer 2026 Highlights Panel Discussion
Harold Burstein, MD, PhD; Sara Tolaney, MD, MPH; Erica L. Mayer, MD, MPH; Nancy Lin, MD; and Ana C. Garrido-Castro, MD discuss important breast cancer research presented at the 2026 ESMO Breast Cancer Congress.
Video
2025 San Antonio Breast Cancer Symposium Panel Discussion
Harold Burstein, MD, PhD; Sara Tolaney, MD, MPH; Nancy Lin, MD; Sarah Sammons, MD; Ana C. Garrido-Castro, MD; and Elizabeth Ann Mittendorf, MD, PhD, MHCM, discuss important breast cancer research presented at the 2025 San Antonio Breast Cancer Symposium.
Video
ASCENT-03 Study Presented by Sara Tolaney, MD, MPH
Sara Tolaney, MD, MPH details research in The New England Journal of Medicine showing the ADC sacituzumab govitecan improved outcomes for patients with advanced triple-negative #BreastCancer ineligible for immune checkpoint inhibitors.
Video
ASCO 2023: Breast Cancer Research Presented by Sara Tolaney, MD
Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer.
Video
Welcome Session | 2022-2023 EMBRACE MBC Virtual Forum Series
Nancy Lin, MD; Sara Tolaney, MD, MPH; and patient advocate Lianne Kraemer discuss new developments and promising areas of research in metastatic breast cancer at Dana-Farber and beyond.